Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.
BACKGROUND
Palliative oxygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who are ineligible for long-term oxygen therapy. We assessed the effectiveness of oxygen compared with room air delivered by nasal cannula for relief of breathlessness in this population of patients.


METHODS
Adults from outpatient clinics at nine sites in Australia, the USA, and the UK were eligible for enrolment in this double-blind, randomised controlled trial if they had life-limiting illness, refractory dyspnoea, and partial pressure of oxygen in arterial blood (PaO(2)) more than 7.3 kPa. Participants were randomly assigned in a 1:1 ratio by a central computer-generated system to receive oxygen or room air via a concentrator through a nasal cannula at 2 L per min for 7 days. Participants were instructed to use the concentrator for at least 15 h per day. The randomisation sequence was stratified by baseline PaO(2) with balanced blocks of four patients. The primary outcome measure was breathlessness (0-10 numerical rating scale [NRS]), measured twice a day (morning and evening). All randomised patients who completed an assessment were included in the primary analysis for that data point (no data were imputed). This study is registered, numbers NCT00327873 and ISRCTN67448752.


RESULTS
239 participants were randomly assigned to treatment (oxygen, n=120; room air, n=119). 112 (93%) patients assigned to receive oxygen and 99 (83%) assigned to receive room air completed all 7 days of assessments. From baseline to day 6, mean morning breathlessness changed by -0.9 points (95% CI -1.3 to -0.5) in patients assigned to receive oxygen and by -0.7 points (-1.2 to -0.2) in patients assigned to receive room air (p=0.504). Mean evening breathlessness changed by -0.3 points (-0.7 to 0.1) in the oxygen group and by -0.5 (-0.9 to -0.1) in the room air group (p=0.554). The frequency of side-effects did not differ between groups. Extreme drowsiness was reported by 12 (10%) of 116 patients assigned to receive oxygen compared with 14 (13%) of 108 patients assigned to receive room air. Two (2%) patients in the oxygen group reported extreme symptoms of nasal irritation compared with seven (6%) in the room air group. One patient reported an extremely troublesome nose bleed (oxygen group).


CONCLUSIONS
Since oxygen delivered by a nasal cannula provides no additional symptomatic benefit for relief of refractory dyspnoea in patients with life-limiting illness compared with room air, less burdensome strategies should be considered after brief assessment of the effect of oxygen therapy on the individual patient.


BACKGROUND
US National Institutes of Health, Australian National Health and Medical Research Council, Duke Institute for Care at the End of Life, and Doris Duke Charitable Foundation.
Abernethy
Amy P
AP
Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. amy.abernethy@duke.edu
McDonald
Christine F
CF
Frith
Peter A
PA
Clark
Katherine
K
Herndon
James E
JE
Marcello
Jennifer
J
Young
Iven H
IH
Bull
Janet
J
Wilcock
Andrew
A
Booth
Sara
S
Wheeler
Jane L
JL
Tulsky
James A
JA
Crockett
Alan J
AJ
Currow
David C
DC
D000328:Adult; D000368:Aged; D000388:Air; D001007:Anxiety / Q000139:chemically induced; D001315:Australia; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy / Q000628:therapy*; D004844:Epistaxis / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D010166:Palliative Care / Q000379:methods*; D011788:Quality of Life; D012890:Sleep; D012894:Sleep Stages; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States
D010100:Oxygen
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Int J Chron Obstruct Pulmon Dis. 2006;1(3):289-304
18046866
Chest. 1988 Mar;93(3):580-6
3342669
Palliat Med. 1998 Sep;12(5):333-44
9924596
Chest. 2000 Nov;118(5):1303-8
11083678
Palliat Med. 1997 Jan;11(1):3-20
9068681
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005623
18425927
BMJ. 2003 Sep 6;327(7414):523-8
12958109
Curr Opin Support Palliat Care. 2008 Jun;2(2):89-94
18685402
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004769
18646110
J Appl Physiol (1985). 1988 Jan;64(1):371-6
3128527
Thorax. 2002 Nov;57(11):939-44
12403875
Br J Cancer. 2008 Jan 29;98(2):294-9
18182991
J Pain Symptom Manage. 2000 Aug;20(2):104-12
10989248
Palliat Med. 2003 Dec;17(8):659-63
14694916
J Pain Symptom Manage. 2008 Nov;36(5):451-60
18495412
J Pain Symptom Manage. 2007 Aug;34(2):113-4
17555920
Am J Respir Crit Care Med. 1996 May;153(5):1515-8
8630595
Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006429
21678356
Med J Aust. 1998 Jan 5;168(1):21-5
9451391
Am J Respir Crit Care Med. 1999 Jan;159(1):321-40
9872857
Pain. 1983 Oct;17(2):197-210
6646795
Ann Intern Med. 1997 Jan 15;126(2):97-106
9005760
Med Care. 2003 May;41(5):582-92
12719681
Palliat Med. 2005 Mar;19(2):168-70
15810762
J Pain Symptom Manage. 2002 Jun;23(6):484-9
12067772
Am J Respir Crit Care Med. 2007 Aug 15;176(4):343-9
17446339
Chest. 1995 Feb;107(2):301-2
7842750
Am Rev Respir Dis. 1987 Jul;136(1):58-61
3605841
Chest. 2004 Jan;125(1):77-84
14718424
JAMA. 2001 Mar 14;285(10):1331-7
11255389
Respir Med. 2004 Jan;98(1):66-77
14959816
J Burn Care Rehabil. 2003 Nov-Dec;24(6):403-6; discussion 402
14610429